GlassScriptPhysician profile
Hemant Sreenivasa Murthy
NPI 1518129188
$64,209.85
in general payments reported to CMS, 2019-2025
28 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $604 · 2021: $4,503 · 2022: $431 · 2023: $7,478 · 2024: $11K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $49K · Food and Beverage: $4,627 · Travel and Lodging: $1,668 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,550 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $48,972.00 |
| Food and Beverage | $4,627.05 |
| Travel and Lodging | $1,668.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,550.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $15,661.56 | 2020-2025 | Yescarta |
| Genzyme Corporation | $10,116.21 | 2019-2025 | |
| Geron Corporation | $7,929.11 | 2025 | Imetelstat, Rytelo |
| E.R. Squibb & Sons, L.L.C. | $5,441.00 | 2020-2024 | |
| Acceleron Pharma, INC. | $4,225.00 | 2021 | |
| Sobi, INC | $4,111.94 | 2024 | |
| Syndax Pharmaceuticals, INC. | $3,616.28 | 2025 | Revuforj |
| National Marrow Donor Program | $2,892.80 | 2022-2025 | |
| Incyte Corporation | $2,788.79 | 2023-2024 | Jakafi |
| Bavarian Nordic A/S | $2,020.00 | 2023 | |
| Celgene Corporation | $1,500.00 | 2023 | |
| Abbvie INC. | $725.00 | 2025 | |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Aimmune Therapeutics, INC. | $625.00 | 2025 | Vowst |
| Rigel Pharmaceuticals, INC. | $345.63 | 2025 | Gavreto, Rezlidhia, Tavalisse |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $302.32 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $250.76 | 2024-2025 | |
| Genentech, INC. | $196.85 | 2023 | Venclexta |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $146.39 | 2020-2021 | |
| Pfizer INC. | $114.53 | 2024 | |
| Aveo Pharmaceuticals, INC. | $99.99 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $93.12 | 2023 | |
| Genentech USA, INC. | $71.63 | 2024 | |
| Amgen INC. | $58.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $50.00 | 2025 | |
| Aurobindo Pharma USA, INC. | $27.11 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemant Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.